Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly
EHA Learning Center, Hartmut Goldschmidt, 219201
What are the treatment goals and optimal endpoints in RRMM
EHA Learning Center, Thierry FACON, 219202
How I manage extramedullary disease and plasma cell leukemia
EHA Learning Center, María-Victoria Mateos, 219203
Biology of secondary leukemia
EHA Learning Center, Timothy Graubert, 219205
Impact of underlying disease on secondary leukemia
EHA Learning Center, Lene Sofie Granfeldt Østgård, 219206
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIC PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
EHA Learning Center, Esther Natalie Oliva, 214478
OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PRIOR BLINATUMOMAB IN ZUMA-3, A STUDY OF KTE-C19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
EHA Learning Center, Olalekan O. Oluwole, 214484
CHEMOTHERAPY AND VENETOCLAX IN ELDERLY AML TRIAL (CAVEAT): A PHASE 1B DOSE ESCALATION STUDY EXAMINING MODIFIED INTENSIVE CHEMOTHERAPY IN FIT ELDERLY PATIENTS
EHA Learning Center, Andrew Wei, 214491
TP53 MUTATION HAD A NEGATIVE PROGNOSTIC IMPACT IN UNTREATED YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AT HIGH-RISK: A SUB-ANALYSIS OF FIL-DLCL04 STUDY
EHA Learning Center, Annalisa Chiappella, 214569
GENOMIC ALTERATIONS IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA FREQUENTLY AFFECT CELL CYCLE KEY REGULATORS AND NOTCH1 REGULATED TRANSCRIPTION.
EHA Learning Center, Jennifer Edelmann, 214583
THE FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
EHA Learning Center, Helen Papadaki, 214588
NOVEL INSIGHTS INTO SPLEEN INJURY DURING THE FIRST 2 YEARS OF LIFE IN SCA CHILDREN: A LONGITUDINAL STUDY
EHA Learning Center, Sara El Hoss, 214590
SINGLE-CELL PROFILING REVEALS KEY DIFFERENCES IN THE CELLULAR ARCHITECTURE OF HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS THROUGHOUT FETAL AND ADULT LIFE
EHA Learning Center, Anindita Roy, 214591
THE MUTATIONAL LANDSCAPE IN HYDROXYCARBAMIDE-RESISTANT/INTOLERANT ESSENTIAL THROMBOCYTHEMIA TREATED ON THE MAJIC-ET STUDY
EHA Learning Center, Jennifer O'Sullivan, 214619
PRECLINICAL EVALUATION OF THE NEW BCMAXCD3 BISPECIFIC ANTIBODY JNJ-957 FOR THE TREATMENT OF MULTIPLE MYELOMA
EHA Learning Center, Kristine Frerichs, 214621
PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, David Sallman, 214477
DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214482
PERSISTENT BCR-ABL1 CLONAL HEMATOPOIESIS AFTER BLAST CLEARANCE IDENTIFIES A CML-LIKE SUBGROUP OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ALL: INTERIM RESULTS FROM THE GRAAPH-2014 TRIAL
EHA Learning Center, Emmanuelle Clappier, 214483
FAVOURABLE OUTCOMES WITH R-CODOX-M/R-IVAC ACROSS ALL SUBGROUPS OF AGGRESSIVE HIGH GRADE B-CELL LYMPHOMA: PATHOLOGY AND UPDATED SURVIVAL RESULTS FROM A PHASE 2 UK NCRI/LLR TRIAL
EHA Learning Center, Elizabeth Phillips, 214487
SIMULTANEOUS TARGETING OF MCL-1 (S63845) AND BCL-2 (VENETOCLAX) ANTI-APOPTOTIC PROTEINS IN MULTIPLE MYELOMA
EHA Learning Center, Esperanza Algarín, 214498
PERIVASCULAR NICHE CELLS SENSE THROMBOCYTOPENIA AND ACTIVATE PLATELET-BIASED HSCS IN AN IL-1 DEPENDENT MANNER
EHA Learning Center, Tiago Cunha Luis, 214499
THE COMBINATION OF THE MDM2 ANTAGONIST, IDASANUTLIN WITH NILOTINIB TARGETS PRIMITIVE CHRONIC MYELOID LEUKEMIA (CML) CELLS IN VITRO AND IN VIVO.
EHA Learning Center, Mary Scott, 214573
GROWTH DYNAMICS IN NATURALLY PROGRESSING CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Michaela Gruber, 214582
PROGNOSTIC FACTORS FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE
EHA Learning Center, Rafal Machowicz, 214623
GENOME WIDE ASSOCIATION STUDIES (GWAS) OF CEREBROVASCULAR EVENTS IN PATIENTS WITH SICKLE CELL ANAEMIA (SCA)
EHA Learning Center, John Brewin, 214626
IMETELSTAT IN RBC TRANSFUSION-DEPENDENT (TD) LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESA) (IMERGE): UPDATED EFFICACY AND SAFETY
EHA Learning Center, Pierre Fenaux, 214476
MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Courtney D. DiNardo, 214481
MS4A3 REGULATES CELL SURFACE CYTOKINE RECEPTOR EXPRESSION, DIFFERENTIATION, AND DRUG RESISTANCE IN CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Anna Eiring, 214572
GENOME-WIDE ASSOCIATION STUDY REVEALS ANKYRIN REPEAT AND SOCS BOX PROTEIN 3 (ASB3) AND INOSITOL POLYPHOSPHATE MULTIKINASE (IPMK) AS NEW RISK LOCI FOR RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Laura Hinze, 214578
EFFECTS OF DARATUMUMAB ON THE COMPOSITION AND ACTIVATION STATUS OF IMMUNE-CELL POPULATIONS IN CENTAURUS, A PHASE 2 RANDOMIZED STUDY OF SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS
EHA Learning Center, Homer Adams III, 214585
MANAGEMENT OF ELANE-NEUTROPENIA: LIFETIME G-CSF VS HAEMATOPOIETIC STEM CELL TRANSPLANTATION LEARNING LESSON FROM THE EXPERIENCE
EHA Learning Center, Francesca Fioredda, 214587
1 INTRAVASCULAR HEMOLYSIS INDUCES COMPLEMENT SYSTEM ACTIVATION MEDIATED BY HEME AND HEME-LOADED ERYTHROCYTE MICROVESICLES
EHA Learning Center, Lubka Roumenina, 214589
IMPACT OF CONCURRENT FOLLICULAR LYMPHOMA OR OTHER LOW-GRADE B-CELL LYMPHOMA ON THE CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Yucai Wang, 214618
OVEREXPRESSION OF THE TRANSCRIPTION FACTOR CDX2 IN HAEMATOPOIETIC STEM CELLS PREDISPOSES TO HAEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Therese Vu, 214629
INTEGRATED ATAC-SEQ AND SINGLE-CELL SYNERGISTIC CHEMOSENSITIVITY PROFILING IDENTIFIES RATIONAL DRUG COMBINATIONS IN IBRUTINIB-TREATED CLL PATIENTS
EHA Learning Center, Gregory Vladimer, 214638
ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Daniel A. Pollyea, 214480
SURVIVAL OF VERY ELDERLY PATIENTS WITH DLBCL ACCORDING TO TREATMENT INTENSITY IN THE RITUXIMAB ERA: A SWEDISH LYMPHOMA REGISTRY STUDY
EHA Learning Center, Kristina Sonnevi, 214568
JAK1-STAT3 SIGNALING AXIS SUPPORTS LEUKEMIC STEM CELL PERSISTENCE IN CML
EHA Learning Center, Mirle Schemionek, 214571
A RANDOMIZED PHASE II STUDY OF STANDARD DOSE AZACITIDINE ALONE OR IN COMBINATION WITH LENALIDOMIDE IN HIGH-RISK MDS WITH A KARYOTYPE INCLUDING DEL(5Q)
EHA Learning Center, Bengt Rasmussen, 214575
A NOVEL, INTEGRATED AND VALIDATED PROGNOSTIC INDEX FOR PREDICTING OUTCOME IN ACUTE LYMPHOBLASTIC LEUKAEMIA PROVIDES NEW APPROACH FOR RISK STRATIFICATION.
EHA Learning Center, Anthony Moorman, 214577
CLINICAL IMPORTANCE OF DNA METHYLATION SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY
EHA Learning Center, J.C. Strefford, 214580
EXPRESSION OF PROTEINS IN CD138+ PLASMA CELLS PREDICTS PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VRD REGIMEN.
EHA Learning Center, Irena Misiewicz-Krzeminska, 214584
CHARACTERIZATION OF ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITORS OF COMPLEMENT C5
EHA Learning Center, Alonso Ricardo, 214586
THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA
EHA Learning Center, Inge Baas, 214625
P53 DEFICIENCY DRIVES LEUKEMIC TRANSFORMATION OF HEMATOPOIETIC STEM CELLS BY MAINTAINING QUIESCENCE IN RESPONSE TO DNA DAMAGE
EHA Learning Center, Andreas Brown, 214628
IVOSIDENIB (AG-120) IN MUTANT IDH1 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF A PHASE 1 STUDY
EHA Learning Center, Daniel A. Pollyea, 214479
RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA
EHA Learning Center, Michael Pfreundschuh, 214567
THE TUMOR SUPPRESSOR MIR-300 PRESERVES CANCER STEM CELLS AND INHIBITS NK CELL ANTICANCER IMMUNITY
EHA Learning Center, Danilo Perrotti, 214570
A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME
EHA Learning Center, Guillermo Garcia-Manero, 214574
OUTCOMES OF YOUNG ADULT (≥ 18-25 YEARS) AND PEDIATRIC (<18 YEARS) PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
EHA Learning Center, Susana Rives, 214576
LINKING ABERRANT CHROMATIN FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA TO DEREGULATED TRANSCRIPTION FACTOR NETWORKS
EHA Learning Center, Viola Meyer-Pannwitt, 214579
THE CHRONOLOGICAL ORDER OF COPY NUMBER CHANGES IN HYPERDIPLOID MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Francesco Maura, 214620
A COHORT OF 22 PATIENTS WITH SAMD9/SAMD9L DISORDER: BONE MARROW FAILURE AND MDS PREDISPOSITION WITH TRANSIENT MONOSOMY 7
EHA Learning Center, Marie Sébert, 214622
RED CELL EFFECTS OF THE ANTI-CD47 MONOCLONAL ANTIBODY HU5F9-G4 IN A PHASE I STUDY FOR RELAPSED OR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Charlotte Brierley, 214624
SPECIFICATION OF HEMATOPOIETIC STEM CELL FATE VIA MODULATION OF MITOCHONDRIAL ACTIVITY
EHA Learning Center, Mukul Girotra, 214627
GENE EXPRESSION PROFILING IDENTIFIES CHARACTERISTIC TRANSCRIPTIONAL SIGNATURES OF GENOMIC INSTABILITY IRRESPECTIVE OF TP53 IMPAIRMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Johannes Bloehdorn, 214639
ROLE OF MTORC1 IN NORMAL HAEMOPOIESIS AND LEUKAEMOGENESIS
EHA Learning Center, Natasha Malik, 214655
CLONAL EVOLUTION OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS FROM DIAGNOSIS TO RELAPSE
EHA Learning Center, shumaila sayyab, 215239
REFINED DETECTION AND PHASING OF STRUCTURAL ABERRATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH LINKED-READ WHOLE GENOME SEQUENCING
EHA Learning Center, Yanara Marincevic-Zuniga, 215240
PROTEOLYTIC L-ASPARAGINASE DEGRADATION AS A MECHANISM FOR NON-ANTIBODY-RELATED DRUG INACTIVATION
EHA Learning Center, Justyna Walenciak, 215256
EXTRAMEDULLARY LATE RELAPSES IN ATYPICAL SITES OF ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP)
EHA Learning Center, Giovanna Giagnuolo, 215257
SYNERGISTIC INHIBITORY EFFECT OF HYDROXYUREA AND DECITABINE ON THE PROLIFERATION OF AML CELLS
EHA Learning Center, Konstantin Byrgazov, 215273
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA USING MULTIPARAMETRIC FLOW CYTOMETRY IS HIGHLY PREDICTIVE OF OUTCOME
EHA Learning Center, Chinmayee Kakirde, 215274
IDENTIFICATION OF GENE COPY NUMBER ABERRATIONS AS PROGNOSTIC MARKERS OF SURVIVAL IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS BY EXOME SEQUENCING OF LEUKEMIA DNA IN THE MAYO CLINIC AML EPIDEMIOLOGY COHORT
EHA Learning Center, Yan Asmann, 215290
NEO2734, A NOVEL HIGHLY POTENT ORAL DUAL BET AND P300/CBP BROMODOMAIN INHIBITOR FOR TREATMENT OF HEMATOLGICAL MALIGNANCIES
EHA Learning Center, Bill Brown, 215291
PH II TRIAL WITH SELECTIVE ORAL AXL INHIBITOR BEMCENTINIB (BGB324) IN RELAPSED/REFRACTORY AML AND MDS: IDENTIFICATION OF PREDICTIVE AND PHARMACODYNAMIC BIOMARKER CANDIDATES ASSOCIATED WITH PT BENEFIT
EHA Learning Center, Julia Schoelermann, 215306
CYTOGENETIC AND MOLECULAR DRIVERS OF OUTCOME WITH VENETOCLAX-BASED COMBINATION THERAPIES IN TREATMENT-NAÏVE ELDERLY PATIENTS WITH AML
EHA Learning Center, Stephen Strickland, 215307
ANALYSIS OF PHASE I AND PILOT PHASE II DATA REVEAL 2,000 MG/M2 AS THE OPTIMAL DOSE OF CPI-613 IN COMBINATION WITH CYTARABINE AND MITOXANTRONE FOR ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Learning Center, Timothy Pardee, 215322
EXTRACELLULAR CIRCULATING DNA IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: BIOLOGICAL CORRELATES AND PROGNOSTIC IMPACT
EHA Learning Center, Dino Dujmovic, 215338
CLINICAL FEATURES, TREATMENT AND PROGNOSTIC FACTORS FOR EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA, NASAL TYPE, IN THE SPANISH POPULATION. A STUDY FROM THE SPANISH GROUP GELTAMO.
EHA Learning Center, EVA GONZALEZ BARCA, 215354
DISSEMINATED INTRAVASCULAR COAGULATION SCORING IN CHILDREN WITH ACUTE LEUKEMIA: IS THERE A SIMPLER AND ECONOMICAL ALTERNATIVE?
EHA Learning Center, Yasmine El Chazli, 215370
OPTIMIZING MRD RESPONSE ASSESSMENT USING HIGH-SENSITIVITY PERIPHERAL BLOOD MONITORING DURING TREATMENT WITH IBRUTINIB COMBINED WITH OBINUTUZUMAB OR VENETOCLAX IN CLL .
EHA Learning Center, Andy C. Rawstron, 215386
HIGHER RESPONSIVENESS OF CLL CELLS TO B-CELL RECEPTOR STIMULATION IS ASSOCIATED WITH REDUCED EXPRESSION OF INHIBITORY MOLECULES OF THE NF-ΚB PATHWAY
EHA Learning Center, Ruud Meijers, 215403
T-LARGE GRANULAR LYMPHOCYTIC (T-LGL) LEUKEMIA: A LONG-TERM STUDY ON 51 PATIENTS-COULD WE CONFINE THE USE OF THE TERM “LEUKEMIA”?
EHA Learning Center, Xanthi Yiakoumis, 215419
MAINTENANCE THERAPY WITH DASATINIB ADMINISTRATED EVERY OTHER DAY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Clemence Loiseau, 215435
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468
NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
EHA Learning Center, Carmelo Carlo-Stella, 215484
CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD
EHA Learning Center, Sara Montesdeoca Romero, 215500
CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER
EHA Learning Center, Karla Jakobac, 215518
GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE
EHA Learning Center, Uta OELSCHLAEGEL, 215534
HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
EHA Learning Center, Liat shargian-alon, 215550
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
EHA Learning Center, Muntasir Majumder, 215567
TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Cinzia Federico, 215583
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.
EHA Learning Center, Francesca Gay, 215599
TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE
EHA Learning Center, Richa Manwani, 215615
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE

EHA Learning Center, Angelo Belotti, 215631
NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS
EHA Learning Center, Alfio Bonanno, 215647
MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY
EHA Learning Center, Caroline Mcnamara, 215663
DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2
EHA Learning Center, Junya Kuroda, 215680
RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B
EHA Learning Center, Wan-Yi Zhai, 215697
OCCURRENCE AND MANAGEMENT OF HEPATOBILIARY ADVERSE EVENTS (AES) IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING LONG-TERM TREATMENT WITH ELTROMBOPAG: RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Abderrahim Khelif, 215714
A HEALTH STATE UTILITY MODEL ESTIMATING THE IMPACT OF IVOSIDENIB ON QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michael Storm, 215730
TICAGRELOR VERSUS PLACEBO FOR THE REDUCTION OF VASO-OCCLUSIVE CRISES IN PEDIATRIC SICKLE CELL DISEASE: DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER PHASE 3 STUDY (HESTIA3)
EHA Learning Center, Matthew Heeney, 215747
COMBINED EVALUATION OF DISEASE RISK INDEX AND ABCG2 EXPRESSION IDENTIFY AML PATIENTS AT A VERY HIGH RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Daniela Damiani, 215763
LIFESTYLE BEHAVIOR AMONG LYMPHOMA SURVIVORS AFTER HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hanne Bersvendsen, 215779
SERUM YKL-40 LEVELS IN PATIENTS WITH B-THALASSEMIA: RELATION TO VIRAL HEPATITIS, LIVER STIFFNESS AND HEPATIC IRON CONCENTRATION.
EHA Learning Center, Samah Mostafa, 215795
THE INFLUENCE OF PGP AND PGR PEPTIDES ON ANTICOAGULANT CAPACITY AND ANTITHROMBOTIC POTENTIAL OF BLOOD IN HEMOSTATIC DYSFUNCTION OF AGING RATS
EHA Learning Center, Tamara Obergan, 215812
AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL
EHA Learning Center, Yuzhe Shi, 215892
BONE MARROW FAILURE AND PREDISPOSITION TO LEUKEMIA IN GATA2 HAPLOINSUFFICIENT MICE
EHA Learning Center, Julia Weiss, 215908

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings